本报记者 刘钊 对不少肿瘤患者而言，最难的并非某一次治疗本身，而是出院后的"漫长空窗期"：复查节点如何安排、 化疗副作用如何监测、检验报告怎么看、夜间突发不适找谁咨询……现实中，医疗服务的"时空限 制"与"服务断层"，常常让患者在院外陷入"失管"困局。 在此背景下，盈康生命科技股份有限公司（以下简称"盈康生命"）发布肿瘤全周期管理智能体，并提出 以此为核心载体推进战略升级，在医疗服务板块实现从诊疗场所到提供健康导航系统的主动健康管理生 态平台。 围绕战略升级的底层逻辑、产品如何真正实现"线上+线下"融合以及商业闭环如何跑通等问题，《证券 日报》记者近日专访了盈康生命董事兼总经理马安捷。 打造"专属AI私人医生" 盈康生命成立于1998年，于2010年登陆深交所创业板，2019年公司实际控制人变更为海尔集团。在医疗 服务端，公司经营及管理着11家医疗机构。在器械端，公司围绕肿瘤"预/诊/治/康"关键场景布局放射治 疗、生命支持、影像增强、慢病治疗等产品线。 这种"从工具到供给侧变革"的判断，也体现在公司对AI底座的描述上。马安捷提到，盈康生命正在 以"盈康大脑"为智慧中枢，形成"算力与数据湖—能力组件—智能交互 ...

证券日报网讯 2月25日，盈康生命在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 总数为24872户。 （文章来源：证券日报） ...

证券日报网讯2月3日，盈康生命（300143）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司股东总数为24659户。 ...

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Core Viewpoint - Yingkang Life (300143) emphasizes its commitment to monitoring advancements in cutting-edge technologies and public health needs, indicating a cautious approach to exploring new opportunities based on social value, technical feasibility, and business synergy [1] Group 1 - The company is attentive to the development of frontier technologies and public health demands [1] - Any expansion into new areas will undergo careful research and validation across multiple dimensions [1] - The company will fulfill its disclosure obligations in accordance with regulations if there are substantial developments in this field that meet disclosure standards [1]

证券日报网讯1月21日，盈康生命（300143）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总数为25816户。 ...

（编辑 任世碧） 证券日报网讯 1月16日，盈康生命在互动平台回答投资者提问时表示，公司高度重视人口老龄化趋势带 来的发展机遇，积极发展护理养老产业，并通过区域医疗中心和数字化平台建设，实现严肃医疗-重症 康复-护理养老的全场景医疗服务产业闭环及能力建设。护理养老业务目前以上海盈康护理集团为依 托，已托管上海盈康和徐泾护理院等。护理养老业务聚焦中西医结合诊疗特色和打造无味化"家的感 觉"，形成1+N（机构）+n（居家）的能力拓展，并受到政府的高度认可。其中，徐泾镇养护院作为承 接上海市青浦区徐泾镇首家"家庭照护床位服务"试点，将专业照护服务延伸至老年人家中。公司将继续 关注护理养老产业的发展趋势和政策导向，抓住人口老龄化的银发经济机会，结合老年用户的医疗保健 需求，向养老护理化到护理医院化方向发展，优化现有业务结构，以实现康养业务的高质量及可持续发 展。 ...

Group 1 - The core point of the news is that Yingkang Life's stock has experienced a decline of 5.04% on January 16, with a total market value of 9.181 billion yuan and a cumulative drop of 2.86% over three consecutive days [1] - Yingkang Life, established on August 6, 1998, and listed on December 9, 2010, is based in Qingdao, Shandong Province, and specializes in medical devices and services, particularly in cancer prevention, diagnosis, treatment, and rehabilitation [1] - The company's revenue composition shows that medical services account for 77.47%, while medical devices and consumables each contribute 22.53% [1] Group 2 - From the perspective of fund holdings, one fund under Galaxy Fund has a significant position in Yingkang Life, with a reduction of 117,700 shares in the third quarter, holding 813,200 shares, which represents 4.72% of the fund's net value [2] - The fund, Galaxy Kangle Stock A (519673), has reported a year-to-date return of 24.87% and a one-year return of 48.73%, ranking 13th out of 5,531 in its category [2] - The fund manager, Fang Wei, has been in position for 4 years and 253 days, with the fund's total asset size at 703 million yuan [3]

Group 1 - The core point of the article is that Yingkang Life (300143) reported a total of 26,187 shareholders as of January 9, 2026 [1]

Core Viewpoint - The company is actively monitoring the application and development of cutting-edge technologies, including brain-computer interfaces, in the healthcare sector, and is committed to a cautious and pragmatic layout based on clinical value and long-term strategic direction [1] Group 1: Company Developments - The company has established a comprehensive management plan for Parkinson's disease treatment using brain-computer interfaces, covering preoperative screening, intraoperative implementation, postoperative monitoring, and rehabilitation [1] - The company's affiliated Yuncheng Hospital has successfully completed over 20 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] Group 2: Technological Innovations - The company-managed Shanghai Yongci Rehabilitation Hospital has collaborated with Fourier to create a leading domestic rehabilitation robot IoT port [1] - The rehabilitation robot, as the core device of the IoT port, offers highly personalized rehabilitation services, enhances rehabilitation efficiency, and effectively optimizes the allocation of human resources for rehabilitation therapists [1] Group 3: Commitment to Transparency - The company adheres to an open and win-win ecological philosophy and will fulfill its information disclosure obligations in a timely manner according to legal regulations and supervisory requirements for any significant developments [1]